TORONTO, ON / ACCESS Newswire / June 23, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leader in AI-powered physiological signal interpretation, is ...
TORONTO, ON / ACCESS Newswire / March 25, 2026 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Illustration by Anumana // Why bring AI into a test that has been around for a hundred years ...
Patent establishes IP across all major amyloidosis subtypes and transforms the standard 12-lead ECG into a screening tool for one of cardiology’s most underdiagnosed diseases AccurKardia, Inc., an ECG ...
An AI-driven app, which analyses standard electrocardiogram results for signs of atrial fibrillation, is being rolled out at hospitals in Japan with the hope of improving detection and saving lives.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI™ algorithm for cardiac amyloidosis (CA) ...
AccurKardia, Inc., an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced that it has been granted US Patent No. 12,620,488 for the company's proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results